Portal de Periódicos da CAPES

The Expression Level of PD-L1 (CD274) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer

2020; International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts; Volume: 40; Issue: 7 Linguagem: Inglês

10.21873/anticanres.14362

1791-7530

Takaaki Masuda, Miwa Noda, Akihiro Kitagawa, Qingjiang Hu, Atsushi Fujii, Shuhei Ito, Keisuke Kosai, Yukio Ando, Yoshihiro Matsumoto, Hajime Ohtsu, Hiroki Uchida, Shinji Ohno, Koshi Mimori,

Immunotherapy and Immune Responses

Background/Aim: Programmed death-ligand 1 (PD-L1/CD274) elicits T-cell anergy, leading to immune suppression. We aimed to determine the prognostic relevance of PD-L1 expression in the blood of breast cancer (BC) patients. Materials and Methods: We measured PD-L1 mRNA expression in blood and tumor tissues of BC patients using RT-qPCR and a dataset from The Cancer Genome Atlas, and performed a survival analysis of PD-L1 expression in the blood of 330 BC patients. Flow cytometric analysis was performed using blood cells. Results: No statistical difference in PD-L1 expression was seen between normal controls and BC in blood or tissues. There was a significant positive correlation between the PD-L1 expression levels in blood and tissues. Decreased PD-L1 expression in blood or tissues was associated with poor recurrence-free survival. PD-L1 is mainly expressed in polymorphonuclear leukocytes. Conclusion: Low expression of PD-L1 in the blood could serve as a biomarker of poor prognosis in BC patients.